- LASOFOXIFENE HCL
-
- $5.50 / 1KG
-
2020-01-13
- CAS:190791-29-8
- Min. Order: 1KG
- Purity: 98%min
- Supply Ability: 1kg-100kg
|
| | LASOFOXIFENE HCL Basic information |
| Product Name: | LASOFOXIFENE HCL | | Synonyms: | 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt);2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5R-cis)-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1) (salt);Cb 336156eb;Unii-85X09V2gso;(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate (1:1);(-)-cis-6-Phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol tartrate;(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol tartrate;CP-336,156 tartrate | | CAS: | 190791-29-8 | | MF: | C32H37NO8 | | MW: | 563.65 | | EINECS: | | | Product Categories: | | | Mol File: | 190791-29-8.mol |  |
| | LASOFOXIFENE HCL Chemical Properties |
| Melting point | 185 °C(dec.) | | storage temp. | 2-8°C | | solubility | DMSO: soluble10mg/mL, clear | | form | powder | | color | white to beige |
| WGK Germany | 3 | | HS Code | 2933.99.7500 |
| | LASOFOXIFENE HCL Usage And Synthesis |
| Uses | disintegrant, enteric coating, sustained release formulations | | Biological Activity | lasofoxifene (tartrate) is a third-generation, nonsteroidal selective estrogen receptor modulator (serm).estrogen receptors are activated by the hormone estrogen (17β-estradiol). serms are characterized by having estrogen agonist action in some tissues while acting as estrogen antagonists in others [1][2].lasofoxifene, also known as cp 336,156, is a third-generation, nonsteroidal selective estrogen receptor modulator. lasofoxifene bound with high affinity to the human estrogen receptor-α with ic50 value of 1.5 nm [1]. lasofoxifene is also a cb2 inverse agonist [4].in aged female rats, lasofoxifene decreased total serum cholesterol and fat body mass, and no uterine hypertrophy was observed. in 5-month-old ovariectomized (ovx) sprague-dawley female rats, lasofoxifene completely prevented ovx-induced increases in body weight gain, total serum cholesterol, and serum osteocalcin. cp-336,156 completely prevented ovx-induced bone loss and inhibited the increased bone turnover associated with estrogen deficiency in lumbar vertebrae, proximal tibiae, and distal femora [1].in postmenopausal women with osteoporosis, lasofoxifene reduced risks of nonvertebral and vertebral fractures, er-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events [2][3]. | | Biochem/physiol Actions | Lasofoxifene is a third-generation selective estrogen receptor modulator (SERM). | | references | [1]. ke hz, paralkar vm, grasser wa, et al. effects of cp-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. endocrinology. 1998 apr;139(4):2068-76.
[2]. cummings sr, ensrud k, delmas pd, et al. lasofoxifene in postmenopausal women with osteoporosis. n engl j med. 2010 feb 25;362(8):686-96.
[3]. gennari l, merlotti d, nuti r. selective estrogen receptor modulator (serm) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. clin interv aging. 2010 feb 2;5:19-29.
[4]. kumar p, song zh. cb2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene. biochem biophys res commun. 2014 jan 3;443(1):144-9. |
| | LASOFOXIFENE HCL Preparation Products And Raw materials |
|